IL6 and Fabry disease: As a cost-effective alternative to monoclonal antibodies inhabiting specific interleukins like IL-6, colchicine may warrant further exploration in FD specifically, although potential use may be constrained by gastrointestinal intolerance, already a common issue in FD.